Tackling KRAS-mutated non-small-cell lung cancer: iteration and exploration.

Lancet Respir Med

UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA. Electronic address:

Published: August 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(24)00116-4DOI Listing

Publication Analysis

Top Keywords

tackling kras-mutated
4
kras-mutated non-small-cell
4
non-small-cell lung
4
lung cancer
4
cancer iteration
4
iteration exploration
4
tackling
1
non-small-cell
1
lung
1
cancer
1

Similar Publications

The use of cetuximab anti-epidermal growth factor receptor (anti-EGFR) antibodies has opened the era of targeted and personalized therapy in colorectal cancer (CRC). Poor response rates have been unequivocally shown in mutant KRAS and are even observed in a majority of wild-type KRAS tumors. Therefore, patient selection based on mutational profiling remains problematic.

View Article and Find Full Text PDF